|1.||Tsubota, Kazuo: 3 articles (04/2015 - 10/2012)|
|2.||Nakamura, Masatsugu: 2 articles (07/2012 - 08/2002)|
|3.||Yerxa, B R: 2 articles (11/2004 - 04/2001)|
|4.||Kellerman, Donald J: 2 articles (01/2004 - 01/2002)|
|5.||Joo, Choun-Ki: 1 article (02/2016)|
|6.||Joo, Jong-Soo: 1 article (02/2016)|
|7.||Mok, Jee-Won: 1 article (02/2016)|
|8.||Byun, Yong-Soo: 1 article (02/2016)|
|9.||Whang, Woong-Joo: 1 article (02/2016)|
|10.||Choi, Jun-Sub: 1 article (02/2016)|
|1.||Eye Diseases (Eye Disease)
07/01/2012 - "Diquafosol was effective in the treatment of dry eye disease at an optimal dose of 3% six times a day. "
01/01/2014 - "Three percent diquafosol ophthalmic solution appears to be effective in the treatment of ocular surface disease in this age-related dry eye disease mouse model."
06/01/2006 - "The P2Y2-agonist diquafosol is used for the treatment of the dry eye disease. "
11/01/2004 - "Diquafosol has a favorable risk/benefit profile in a broad spectrum of patients with dry eye disease and is a novel topical treatment of dry eye."
08/01/2002 - "INS365 significantly suppressed corneal damage at concentrations of more than 0.1% w/v. These results suggest that this P2Y2 agonist is a good candidate for the treatment of dry eye disease."
10/01/2014 - "Four-week pretreatment with diquafosol 3.0% ophthalmic solution in patients with senile cataract scheduled for cataract surgery with IOL implantation was effective in enhancing the intraoperative corneal surface wetting property, which suggests improved optical clarity during surgery. "
05/01/2015 - "Diquafosol ophthalmic solution 3 % also demonstrated efficacy in various specific dry eye disorders, including aqueous-deficient dry eye, short tear film break-up time dry eye, obstructive meibomian gland dysfunction, dry eye following laser in situ keratomileusis surgery and dry eye following cataract surgery, as well as in contact lens wearers and visual display terminal users. "
10/01/2014 - "To examine the effects of pretreatment with diquafosol 3.0% ophthalmic solution on corneal surface wetting during cataract surgery with intraocular lens (IOL) implantation in cases of senile cataract. "
|3.||Dry Eye Syndromes (Dry Eye Syndrome)
06/01/2014 - "Diquafosol tetrasodium provides a novel mode of action in dry eye syndrome, including SS, by stimulating the quantity and quality of tear fluid secretion via various mechanisms. "
10/01/2012 - "To investigate the dose-dependent efficacy and safety of diquafosol ophthalmic solution for the treatment of dry eye syndrome. "
10/01/2012 - "Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial."
01/01/2001 - "These effects suggest that INS365 is a potential therapeutic agent for use in the treatment of dry eye syndrome."
10/01/2012 - "Both 1% and 3% diquafosol ophthalmic solutions are considered effective and safe for the treatment of dry eye syndrome."
|4.||Foreign Bodies (Foreign Body)
11/01/2004 - "Significant differences in favor of diquafosol were observed for clearing of foreign body sensation and for worst symptom in secondary data analyses. "
11/01/2004 - "The percentage of subjects with clearing of foreign body sensation (score of 0) was higher at week 6 in subjects treated with 2% diquafosol (21%) compared with placebo (15%), but the difference did not achieve significance (P=0.193). "
10/01/2012 - "We found a significant improvement in BUT (P=0.049, Dunnett test), fluorescein and rose bengal staining scores (P=0.02), and in subjective symptoms (P=0.004 for dry eye sensation, P=0.02 for pain, and P=0.02 for foreign body sensation) 4 weeks after treatment in the diquafosol eyes. "
|1.||Ophthalmic Solutions (Eye Drops)
|5.||Hyaluronic Acid (Hyaluronan)
|1.||Laser In Situ Keratomileusis (LASIK)
|3.||Intraocular Lenses (Intraocular Lens)
|4.||Fluid Therapy (Oral Rehydration Therapy)